Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET

Company Participants

Jenna Cohen - Vice President, Investor Relations

Kate Haviland - Chief Executive Officer

Philina Lee - Chief Commercial Officer

Christy Rossi - Chief Operating Officer

Mike Landsittel - Chief Financial Officer

Becker Hewes - Chief Medical Officer

Conference Call Participants

Dane Leone - Raymond James

Eun Yang - Jefferies

Brad Canino - Stifel

Reni Benjamin - JMP Securities

Salveen Richter - Goldman Sachs

Michael Schmidt - Guggenheim

Derek Archila - Wells Fargo

Ami Fadia - Needham

Mike Ulz - Morgan Stanley

Peter Lawson - Barclays

David Lebowitz - Citi

Chris Raymond - Piper Sandler

Matt Biegler - Oppenheimer

Operator

Good morning. My name is Elliot and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines' Third Quarter 2023 Financial Results Conference Call. All lines have been on placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]

I'll now turn it over to Jenna Cohen Vice President of Investor Relations.

Jenna Cohen

Thank you, Elliott and good morning everyone. Welcome to Blueprint Medicines' third quarter 2023 financial and operating results conference call. This morning we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Joining me are Kate Haviland, Chief Executive Officer; Lena Lee, Chief Commercial Officer; Christy Rossi, Chief Operating Officer; and Mike Landsittel, Chief Financial Officer. Suad Namouni, President of Research and Development; and Becker Hewes, Chief Medical Officer will also be available for Q&A.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements as outlined on Slide 3 and are subject to a number of risks and uncertainties. These may cause our actual results to differ materially including those described in our reports filed with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements and Blueprint disclaims any obligation to update such statements.

I'll now hand the call over to Kate.

Kate Haviland

Thank you, Jenna and good morning everyone. A little over two years ago, we first launched AYVAKIT in advanced systemic mastocytosis. And five months ago, we launched AYVAKIT's for indolent systemic mastocytosis. It is clear from both our clinical data and real-world experience now that we're getting with AYVAKIT that AYVAKIT makes a profound difference for patients allowing them to reclaim control of their lives. Everything we are learning today reinforces our belief that AYVAKIT and Blueprint are positioned to achieve long-term leadership with a blockbuster franchise in SM.